S
Sanofi
Sanofi
Sanofi insider trades: Attovia Therapeutics (ATTO) stock buys and sales
Attovia Therapeutics Last trade Aug 6, 2026 69 Form 4 filings
$0
Sold, last 12 months
0 sales
$5.1M
Bought, last 12 months
1 buy
69
Open-market trades
since 2010
14
Companies
last trade 2026
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Sanofi reports to the SEC
LTGOLatigo Biotherapeutics
Insider · last filing Aug 12, 2026
No market trades
ATTOAttovia Therapeutics
Insider · last filing Aug 7, 2026
+$5.1M
TBIOTranslate Bio
10% Owner · last filing Sep 14, 2021
+$2.74B
ICVXIcosavax
10% Owner · last filing Aug 2, 2021
+$1.0M
INZYInozyme Pharma
10% Owner · last filing Jul 29, 2020
+$1.3M
REGNRegeneron Pharmaceuticals
Insider · last filing Jun 11, 2020
-$11.95B
+$2.52B
and 8 more companies
Open-market buys and sales
69 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Aug 6, 2026 | ATTO | ↑ Buy | 300,000 | $17.00 | $5.1M | Indirect | Aug 7, 2026 (1d) |
| Sep 14, 2021 | TBIO | ↑ Buy | 71,983,597 | $38.00 | $2.74B | Direct | Sep 14, 2021 (0d) |
| Aug 2, 2021 | ICVX | ↑ Buy | 66,667 | $15.00 | $1.0M | Through its wholly-owned subsidiary, Ave | Aug 2, 2021 (0d) |
| Jul 28, 2020 | INZY | ↑ Buy | 81,250 | $16.00 | $1.3M | Through its wholly-owned subsidiary, Ave | Jul 29, 2020 (1d) |
| Jun 9, 2020 | REGN | ↓ Sell | 120,234 | $597.48 | $71.8M | See note | Jun 11, 2020 (2d) |
| May 29, 2020 | REGN | ↓ Sell | 20,421,899 | $509.85 | $10.41B | Direct | May 29, 2020 (0d) |
| May 29, 2020 | REGN | ↓ Sell | 2,399,552 | $509.85 | $1.22B | See note | May 29, 2020 (0d) |
| Mar 9, 2020 | REGN | ↓ Sell | 128,914 | $489.65 | $63.1M | Direct | Mar 11, 2020 (2d) |
| Sep 10, 2019 | REGN | ↓ Sell | 172,904 | $281.15 | $48.6M | Direct | Sep 12, 2019 (2d) |
| Jul 22, 2019 | FULC | ↑ Buy | 93,750 | $16.00 | $1.5M | Through its wholly-owned subsidiary, Ave | Jul 23, 2019 (1d) |
| Mar 8, 2019 | REGN | ↓ Sell | 131,115 | $412.17 | $54.0M | Direct | Mar 12, 2019 (4d) |
| Feb 13, 2019 | MYOK | ↓ Sell | 4,168,899 | $37.66 | $157.0M | Via wholly-owned subsidiary, Aventis Inc | Feb 15, 2019 (2d) |
| Sep 6, 2018 | REGN | ↓ Sell | 104,552 | $406.68 | $42.5M | See note | Sep 10, 2018 (4d) |
| Jun 8, 2018 | REGN | ↓ Sell | 121,601 | $309.31 | $37.6M | See note | Jun 11, 2018 (3d) |
| May 25, 2018 | MYOK | ↑ Buy | 150,000 | $49.00 | $7.3M | Via wholly owned subsidiary Aventis Inc. | May 29, 2018 (4d) |
| Aug 25, 2017 | REGN | ↑ Buy | 72,378 | $481.36 | $34.8M | See note | Aug 29, 2017 (4d) |
| Aug 24, 2017 | REGN | ↑ Buy | 166,415 | $480.93 | $80.0M | See note | Aug 25, 2017 (1d) |
| Aug 14, 2017 | MYOK | ↑ Buy | 350,000 | $35.50 | $12.4M | Via wholly owned subsidiary Aventis Inc. | Aug 16, 2017 (2d) |
| Jun 2, 2017 | REGN | ↑ Buy | 136,050 | $478.17 | $65.1M | See note | Jun 6, 2017 (4d) |
| May 31, 2017 | ALNY | ↑ Buy | 297,501 | $71.87 | $21.4M | Via wholly-owned subsidiary, Genzyme Cor | Jun 1, 2017 (1d) |
| Jan 11, 2017 | REGN | ↑ Buy | 87,298 | $369.71 | $32.3M | See note | Jan 13, 2017 (2d) |
| Oct 3, 2016 | MYOK | ↑ Buy | 450,000 | $15.00 | $6.8M | Via wholly owned subsidiary Aventis Inc. | Oct 5, 2016 (2d) |
| Jun 14, 2016 | REGN | ↑ Buy | 64,731 | $363.86 | $23.6M | See note | Jun 16, 2016 (2d) |
| Feb 17, 2016 | REGN | ↑ Buy | 161,157 | $392.46 | $63.2M | See note | Feb 18, 2016 (1d) |
| Feb 1, 2016 | ALNY | ↑ Buy | 205,030 | $69.75 | $14.3M | Via wholly-owned subsidiary, Genzyme Cor | Feb 3, 2016 (2d) |
| Jan 12, 2016 | REGN | ↑ Buy | 83,938 | $465.04 | $39.0M | See note | Jan 14, 2016 (2d) |
| Nov 16, 2015 | VYGR | ↑ Buy | 125,000 | $14.00 | $1.8M | Via wholly owned subsidiary Aventis Inc. | Nov 18, 2015 (2d) |
| Nov 3, 2015 | MYOK | ↑ Buy | 900,000 | $10.00 | $9.0M | Via wholly owned subsidiary Aventis Inc. | Nov 5, 2015 (2d) |
| Oct 6, 2015 | REGN | ↑ Buy | 80,538 | $459.71 | $37.0M | See note | Oct 8, 2015 (2d) |
| Oct 6, 2015 | REGN | ↑ Buy | 11,040 | $472.33 | $5.2M | See note | Oct 8, 2015 (2d) |
| Sep 23, 2015 | REGN | ↑ Buy | 147,209 | $534.67 | $78.7M | See note | Sep 25, 2015 (2d) |
| Jul 27, 2015 | REGN | ↑ Buy10b5-1 | 10,639 | $537.48 | $5.7M | See note | Jul 29, 2015 (2d) |
| Jan 29, 2015 | ALNY | ↑ Buy | 97,118 | $95.00 | $9.2M | Via wholly-owned subsidiary, Genzyme Cor | Feb 2, 2015 (4d) |
| Jan 26, 2015 | ALNY | ↑ Buy | 843,699 | $2240.11 | $1.89B | Via wholly-owned subsidiary, Genzyme Cor | Jan 28, 2015 (2d) |
| Dec 24, 2014 | REGN | ↑ Buy | 201,459 | $393.21 | $79.2M | See note | Dec 29, 2014 (5d) |
| Oct 16, 2014 | REGN | ↑ Buy10b5-1 | 122,127 | $335.35 | $41.0M | See note | Oct 20, 2014 (4d) |
| Oct 15, 2014 | REGN | ↑ Buy10b5-1 | 158,368 | $328.16 | $52.0M | See note | Oct 17, 2014 (2d) |
| Sep 16, 2014 | REGN | ↑ Buy | 31,717 | $349.26 | $11.1M | See note | Sep 18, 2014 (2d) |
| Sep 15, 2014 | REGN | ↑ Buy | 140,632 | $345.15 | $48.5M | See note | Sep 16, 2014 (1d) |
| Jul 15, 2014 | REGN | ↑ Buy10b5-1 | 129,100 | $314.92 | $40.7M | See note | Jul 17, 2014 (2d) |
| Jul 14, 2014 | REGN | ↑ Buy10b5-1 | 300,000 | $316.80 | $95.0M | See note | Jul 15, 2014 (1d) |
| Jul 10, 2014 | REGN | ↑ Buy10b5-1 | 175,000 | $311.08 | $54.4M | See note | Jul 14, 2014 (4d) |
| Jul 9, 2014 | REGN | ↑ Buy10b5-1 | 348,000 | $309.76 | $107.8M | See note | Jul 10, 2014 (1d) |
| Jul 7, 2014 | REGN | ↑ Buy10b5-1 | 356,700 | $312.37 | $111.4M | See note | Jul 8, 2014 (1d) |
| Jul 2, 2014 | REGN | ↑ Buy10b5-1 | 212,400 | $307.25 | $65.3M | See note | Jul 3, 2014 (1d) |
| Jul 1, 2014 | REGN | ↑ Buy10b5-1 | 212,400 | $300.20 | $63.8M | See note | Jul 3, 2014 (2d) |
| Jun 30, 2014 | REGN | ↑ Buy10b5-1 | 262,400 | $281.17 | $73.8M | See note | Jul 1, 2014 (1d) |
| May 19, 2014 | REGN | ↑ Buy | 190,751 | $300.04 | $57.2M | See note | May 21, 2014 (2d) |
| Mar 28, 2014 | REGN | ↑ Buy | 306,945 | $306.73 | $94.1M | See note | Mar 31, 2014 (3d) |
| Mar 27, 2014 | REGN | ↑ Buy | 306,945 | $311.01 | $95.5M | See note | Mar 31, 2014 (4d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other ATTO insiders
Open-market trades in the last 12 months
Goldman Sachs Asset Management, L.P.
Insider
2 buys, 2 sales
Aug 6, 2026
Redmile Group, LLC
10% Owner
1 buy
Aug 6, 2026
Broad Street Principal Investments, L.L.C.
Insider
2 buys, 2 sales
Aug 6, 2026
Jeremy Green
10% Owner
1 buy
Aug 6, 2026
Redmile Biopharma Investments III, L.P.
10% Owner
1 buy
Aug 6, 2026
venBio Global Strategic Fund IV, L.P.
Insider
1 buy
Aug 6, 2026
Colin Walsh
Director
2 buys, 2 sales
Aug 6, 2026
West Street Life Sciences I, L.P.
Insider
2 buys, 2 sales
Aug 6, 2026
About Sanofi's insider trades
Sanofi is an insider at Attovia Therapeutics (ATTO). Since Feb 11, 2010, Sanofi has reported 60 open-market purchases worth $11.37B and 9 sales worth $12.11B on SEC Form 4. In the last 12 months: 1 buy ($5.1M).
Their filings also include conversions (8 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every ATTO insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.